NCNA

NuCana PLC

NCNA, USA

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer; Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer; and Phase 1 modular clinical trial for patients with advanced solid tumors and lung cancer. The company is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is based in Edinburgh, the United Kingdom.

https://www.nucana.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
NCNA
stock
NCNA

NuCana Showcases Promising Results for NUC-7738 in Melanoma Treatment TipRanks

Read more →
NCNA
stock
NCNA

NuCana (NASDAQ: NCNA) reports NUC-7738 activity in PD‑1‑resistant melanoma at ESMO IO Stock Titan

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

HOLD

Target Price:

$104

Analyst Picks

Strong Buy

0

Buy

0

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very High

0.01

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very Low

0.53

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-1.08 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-0.87 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.25

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.20% of the total shares of NuCana PLC

1.

LUNIS Biotech Growth Opp Fd I a

(0.1469%)

since

2024/09/30

2.

Baader Bank INC

(0.0259%)

since

2025/06/30

3.

Cetera Investment Advisers

(0.0216%)

since

2025/06/30

4.

Glass Jacobson Investment Advisors LLC

(0.0039%)

since

2025/06/30

5.

Flagstone Financial Management

(0.0033%)

since

2025/06/30

6.

SBI Securities Co Ltd

(0.0003%)

since

2025/06/30

7.

AllSquare Wealth Management LLC

(0.0001%)

since

2025/06/30

8.

Schonfeld Strategic Advisors LLC

(0%)

since

2025/06/30

10.

Tower Research Capital LLC

(0%)

since

2025/03/31

11.

Citadel Advisors Llc

(0%)

since

2025/03/31

12.

Global Retirement Partners, LLC.

(0%)

since

2025/06/30

14.

Virtu Financial LLC

(0%)

since

2025/03/31

15.

XTX Topco Ltd

(0%)

since

2025/06/30

16.

Acadian Asset Management LLC

(0%)

since

2025/06/30

17.

Rhumbline Advisers

(0%)

since

2025/06/30

18.

Citigroup Inc

(0%)

since

2025/06/30

19.

UBS Group AG

(0%)

since

2025/06/30

21.

The Carlyle Group Inc

(0%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-06-30

EPS Actual

-23.31

EPS Estimate

-13

EPS Difference

-10.31

Surprise Percent

-79.3077%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Strong Deep Value(10)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(3)
Economic Moat
Some Competitive Advantage(5.8)
GARP
Fair GARP(3.5)
Growth
Weak Growth Prospect(2)
Momentum
No Momentum(2.5)
Net Net
Strong Net-Net(9.5)
Quality
Moderate Quality(4.5)
Value
Undervalued(8)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.